Tesamorelin vs Ipamorelin
Which Is Right for You? Complete Comparison (2026)
Tesamorelin vs Ipamorelin comparison — GHRH analog that amplifies hypothalamic GH signaling vs selective GHRP ghrelin receptor agonist.
Tesamorelin vs Ipamorelin: At a Glance
- ✓FDA-approved synthetic GHRH analogue (Egrifta)
- ✓Stimulates natural pulsatile GH release from the pituitary
- ✓Approved specifically for HIV-associated lipodystrophy
- ✓Reduces visceral adipose tissue and liver fat
- ✓Does not cause GH desensitization
- ✓Selective growth hormone releasing peptide (GHRP)
- ✓Stimulates pituitary GH release via ghrelin/GHS-R1a receptor
- ✓Does not significantly elevate cortisol, prolactin, or aldosterone
- ✓Produces a clean GH pulse similar to natural secretion
- ✓Half-life approximately 2 hours — administered 2-3x daily
Detailed Comparison
| Feature | Tesamorelin | Ipamorelin |
|---|---|---|
| Mechanism | GHRH analogue | Growth hormone secretagogue (selective GHRP)Best |
| Dosing | 2 mg SC daily | 200-300 mcg SC 2-3x daily |
| Administration | Subcutaneous injection daily | Subcutaneous injection |
| Half-life | ~26-38 minutes | ~2 hours |
| FDA Status | FDA-approved (Egrifta — for HIV lipodystrophy) | Not FDA-approved — research peptide |
| Key Trial | Falutz J et al. NEJM 2007 — visceral fat reduction in HIV | Raun K et al. Eur J Endocrinol 1998 — demonstrated selective GH release |
| Side Effects | Injection site reactions, joint pain, peripheral edema, paresthesia | Headache, flushing, dizziness, injection site irritation — generally well-tolerated |
Which Should You Choose?
Tesamorelin (Egrifta) (ghrh analogue) and Ipamorelin (growth hormone secretagogue (selective ghrp)) serve different clinical roles despite both being in the GHRH analogue space. Tesamorelin (Egrifta) fda-approved synthetic ghrh analogue that stimulates pulsatile gh release. Ipamorelin selective gh secretagogue that stimulates gh release from the pituitary via ghrelin receptor without significantly raising cortisol, prolactin, or aldosterone.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Tesamorelin and Ipamorelin
Choosing between Tesamorelin and Ipamorelin depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Tesamorelin and Ipamorelin is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Tesamorelin vs Ipamorelin: Frequently Asked Questions
Tesamorelin (Egrifta) is a ghrh analogue while Ipamorelin is a growth hormone secretagogue (selective ghrp). They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
Tesamorelin (Egrifta) works as a ghrh analogue (2 mg SC daily), while Ipamorelin is a growth hormone secretagogue (selective ghrp) (200-300 mcg SC 2-3x daily). They have different half-lives (~26-38 minutes vs ~2 hours), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Tesamorelin or Ipamorelin in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.